<DOC>
	<DOCNO>NCT02695290</DOCNO>
	<brief_summary>There medical need improve treatment poor performance status patient EGFR driver mutation document safety tolerability exist agent .</brief_summary>
	<brief_title>Afatinib EGFR+NSCLC ( Recurrent Stage IV ) - Patients With Poor Performance Status ( ECOG 2 3 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Pathologically cytologically confirm NSCLC Stage IV Cancer ( include cytologically proven pleural effusion pericardial effusion ) recurrent disease . The stag base American Joint Committee Cancer ( AJCC ) Tumor Node Metastatic ( TNM ) classification malignant tumor , 7th edition Evidence common EGFR activate mutation ( Del 19 and/or L858R ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 2 3 Adequate organ function , define follow : Absolute neutrophil count ( ANC ) &gt; 1500 / mm3 Platelet count &gt; 75,000 / mm3 . Baseline creatinine &lt; = 1.5 g/dl , &gt; 1.5 , estimate creatinine clearance &gt; 45 ml/min Total Bilirubin &lt; 1.5 time upper limit institutional normal ( ULN ) Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &lt; three time ULN ( relate liver metastasis &lt; five time ULN ) Recovery previous therapy relate toxicity &lt; = Grade 1 study entry ( except stable sensory neuropathy &lt; =Grade 2 alopecia ) Life expectancy least three month Written inform consent consistent International Council Harmonization Good Clinical Practice ( ICHGCP ) guideline Age 18 old Exclusion criterion : Prior participation afatinib clinical study , even assign afatinib treatment Prior systemic therapy metastatic recurrent NSCLC include prior treatment EGFR target small molecule antibody . Note : radiotherapy alone adjuvant/neoadjuvant treatment count line therapy . Concurrent investigational therapy investigational therapy within 4 week start afatinib therapy Radiotherapy within 4 week prior start study treatment , except follow : . ) Palliative radiation target organ chest may allow 2 week prior study treatment , ii . ) Single dose palliative treatment ( e.g Stereotactic Radio Surgery ( SRS ) Stereotactic Body Radiation Therapy ) ( SBRT ) symptomatic metastasis outside allowance discuss sponsor prior enrol . Major surgery within 4 week start study treatment schedule surgery project course study Women childbearing potential ( WOCBP ) men able father child , use adequate contraception prior study entry , duration study participation least 28 day treatment end . Presence active infection fever &gt; 38.5 C within 3 day first schedule day dose Known hypersensitivity afatinib excipients afatinib Known preexist interstitial lung disease Pathologically document meningeal carcinomatosis ( i.e . cytology ( + ) lumbar puncture ; radiology report alone raise possibility , absence true symptomatology , would constitute exclusion ) Presence brain subdural metastasis , unless local therapy complete use corticosteroid discontinue dose stable least 4 week start study treatment . Any symptom attribute brain metastasis must stable least 4 week start study treatment ( Pts post SRS enrol earlier long symptoms stable improve steroid ) Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 2 year consider cured History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) classification 3 4 unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior treatment afatinib . Any history presence poorly control gastrointestinal disorder could affect absorption study drug ( e.g . Crohn 's disease , ulcerative colitis , chronic diarrhoea , malabsorption ) Known suspect active hepatitis B ( Hep B ) infection ( define presence HepB ( surface Antigen ) sAg and/ Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier Any history concomitant condition , opinion Investigator , would compromise patient 's ability comply study interfere evaluation safety efficacy test drug Treatment prohibit concomitant medication stop duration trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>